Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance
, Gennaro Musi 1, Deliu Victor Matei 1, Alessandro Francesco Mistretta 1, Stefano Luzzago 1, Gabriele Cozzi 1, Roberto Bianchi 1, Ettore Di Trapani 1, Antonio Cioffi 1, Giuseppe Lucarelli 2, Gian Maria Busetto 3, Francesco Del Giudice 4, Giorgio Ivan Russo 5, Marina Di Mauro 5, Angelo Porreca 6, Giuseppe Renne 7, Michele Catellani 1, Danilo Bottero 1, Antonio Brescia 1, Giovanni Cordima 1 and add
Show full author list
Round 1
Reviewer 1 Report
This study was reported the utility of PSIM in patients with low-risk prostate cancer who underwent RARP. The reviewer would like to suggest some critiques as follows.
Major revision
- The reviewer think that the Title is unclear. What is “pathological significant disease”?
- The authors should follow the journal style indicated in the instructions, especially the Reference sections.
- The authors should spell out csPCa, RP, NLR, PLR, LMR, and PSA at the Abstract.
- On page 2, line 33; ofPCa → of PCa
- On page 3, line 31, “At multivariate…..wasn’t found” is unclear. The reviewer think that “ On multivariate analysis, there were no significant differences …” is correct.
Author Response
Dear reviewer thank you for your work.
We modified the text as follow:
1) title has been changed
2) reference section has been adapted to journal style
3) in the abstract we added required abbreviations
4) corrected
5) corrected
Reviewer 2 Report
An interesting manuscript showing an assessment of PSIM score in patients with low risk prostate cancer. In my opinion, It exist many scoring systems which were applied for estimate diagnostic tool in patients with cancerous ethiologies. I think that clearly depends on the patients group selection . Authors well documented use the PSIM score in patients with low risk prostate cancer, nevertheless, My question which authors need to discuss is if the course will be applicable for for patients with pT0-PT1 stage and if is in literature described some corellation with biochemical parmetres including PHI etc. After discussing and comment this minor suggestions, I approve the manuscript for publication.
Author Response
Dear reviewer, thank you for you work.
Regarding your request about applicability of our model to pT0-pT1 patients it wasn't used with these patient, even in literature there isn't anything at this regard. On the other side we added a sentence (in red) and two references regarding correlation with PHI and biochemical parameters.
